CMMB

Chemomab Therapeutics Ltd. Sponsored ADR · NASDAQ

Sector Health Technology
Industry Biotechnology
Website chemomab.com
Employees(FY) -
ISIN US16385C1045

Performance

+27.52%

1W

+57.34%

1M

+58.04%

3M

+91.16%

6M

+109.78%

YTD

-31.85%

1Y

Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Advanced Technical Analysis

Technical Analysis of CMMB 2024-05-31

Overview:

In the last 5 trading days, CMMB stock has shown a consistent upward trend in both price and volume. The moving averages have been steadily increasing, indicating a bullish momentum. Momentum indicators such as RSI and Stochastic oscillators are in overbought territory, suggesting a strong buying pressure. Volatility has also been incr...

See more ...

Recent News & Updates

2024-05-16 19:00
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences(Globenewswire)
2024-05-09 21:55
Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy?(Zacks)
2024-05-08 23:57
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q1 2024(Investorplace)
2024-05-08 19:00
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update(Globenewswire)
2024-05-07 19:00
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule(Globenewswire)
2024-05-01 19:00
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference(Globenewswire)
2024-04-23 19:00
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update(Globenewswire)
2024-04-17 19:00
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis(Globenewswire)
2024-04-01 19:00
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024(Globenewswire)
2024-03-24 19:06
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis(Globenewswire)
2024-03-06 23:53
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q4 2023(Investorplace)
2024-03-06 18:00
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update(Prnewswire)
2024-03-04 18:00
Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference(Prnewswire)
2024-02-19 18:00
Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases(Prnewswire)
2024-02-13 18:00
Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update(Prnewswire)
2024-02-04 18:00
Chemomab Therapeutics to Participate in Upcoming Investor Conferences(Prnewswire)
2024-01-29 18:00
Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis(Prnewswire)
2024-01-02 18:00
Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024(Prnewswire)
2023-11-15 18:00
Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis(Prnewswire)
2023-11-14 18:00
Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis(Prnewswire)
2023-11-12 19:00
Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting 2023(Prnewswire)
2023-11-08 19:00
Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update(Prnewswire)
2023-11-06 03:15
Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement(Prnewswire)
2023-10-29 19:00
Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update(Prnewswire)
2023-10-25 19:00
Chemomab Therapeutics to Present at Upcoming Scientific Conferences(Prnewswire)
2023-09-27 19:00
Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference(Prnewswire)
2023-08-28 19:00
Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference(Yahoo Finance)
2023-08-13 20:00
Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update(Yahoo Finance)
2023-06-27 19:00
Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis(Yahoo Finance)
2023-06-25 19:00
Chemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2023(Yahoo Finance)

Page 1 of 3

previousnext